Market Overview

UPDATE: Oppenheimer Raises PT on Celldex Therapeutics on Key Clinical Milestones, Associated Trials Anticipated In 2H13

Related CLDX
Long-term Survival Benefit Demonstrated in Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma
Celldex Therapeutics Reports Presentation of Varlilumab Mechanism Data at SITC Annual Meeting '15

In a report published on Friday, Oppenheimer analyst Boris Peaker raised the price target on Celldex Therapeutics (NASDAQ: CLDX) from $14 to $16 and reiterated a rating of Outperform on the company.

In the report, Oppenheimer stated, "We believe that investors will be focused on the Rindo studies in brain cancer as well as initial data for CDX-1135 and CDX-1127. Additionally, we performed further due diligence on CDX-1135 and we are adding this compound to our valuation. This is the basis for our price target increase of $2/share (from $14 to $16)."

Celldex Therapeutics closed on Thursday at $14.29.

Latest Ratings for CLDX

Mar 2015JefferiesMaintainsBuy
Mar 2015Cantor FitzgeraldMaintainsBuy
Sep 2014Cowen & CompanyInitiates Coverage onOutperform

View More Analyst Ratings for CLDX
View the Latest Analyst Ratings

Posted-In: Boris Peaker OppenheimerAnalyst Color Price Target Analyst Ratings


Related Articles (CLDX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters